Holen Sie sich die Stockscreener-App
37.48
7.62%
-3.09
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt HROW?
Forum
Prognose
Aktiensplit
Harrow Inc Aktie (HROW) Neueste Nachrichten
Is it too late to sell Harrow Inc.Earnings Growth Report & Real-Time Chart Breakout Alerts - newser.com
What data driven models say about Harrow Inc.’s futurePortfolio Risk Report & Weekly High Conviction Trade Ideas - newser.com
What institutional flow reveals about Harrow Inc.Dollar Strength & Entry and Exit Point Strategies - newser.com
Using data tools to time your Harrow Inc. exitJuly 2025 Movers & Weekly Chart Analysis and Guides - newser.com
Weiss Ratings Reaffirms Sell (E+) Rating for Harrow (NASDAQ:HROW) - MarketBeat
Harrow, Inc. (HROW): A Bull Case Theory - Insider Monkey
Will Harrow's (HROW) Affordability Push and New Leadership Shift its Long-Term Growth Trajectory? - simplywall.st
Could Harrow’s (HROW) New Pricing Program Redefine Its Patient Access Advantage? - Yahoo Finance
ImprimisRx Announces Leadership Changes - GlobeNewswire
Is Harrow Inc. stock dividend yield sustainableWeekly Profit Analysis & Daily Chart Pattern Signal Reports - newser.com
Harrow names Frank Mullery as CEO of ImprimisRx subsidiary - Investing.com
Harrow Health (HROW) Appoints New Leadership at ImprimisRx - GuruFocus
Harrow Health Announces New Leadership at ImprimisRx - TipRanks
Harrow names Frank Mullery as CEO of ImprimisRx subsidiary By Investing.com - Investing.com Canada
ImprimisRx announces leadership changes - MarketScreener
Leadership Appointments at ImprimisRx: Frank Mullery Named CEO and Bridseida Cruz as Head of Quality - Quiver Quantitative
Frank Mullery named CEO; Bridseida Cruz named Head of Quality at ImprimisRx, Harrow subsidiary - Stock Titan
Intraday pattern recognizer results for Harrow Inc.Bull Run & Technical Pattern Recognition Alerts - newser.com
How to escape a deep drawdown in Harrow Inc.July 2025 Sector Moves & Fast Exit Strategy with Risk Control - newser.com
Assessing Harrow’s Value After a 22.8% Surge and Recent Earnings Release - simplywall.st
How to track smart money flows in Harrow Inc.Market Volume Report & Smart Money Movement Alerts - newser.com
Harrow (NASDAQ:HROW) Trading Down 4.9%Should You Sell? - MarketBeat
A Fresh Look at Harrow (HROW) Valuation Following Recent Share Price Momentum - simplywall.st
Harrow, Inc. (NASDAQ:HROW) Looks Just Right With A 27% Price Jump - simplywall.st
Research Analysts Issue Forecasts for Harrow Q3 Earnings - MarketBeat
How to use Fibonacci retracement on Harrow Inc.2025 Top Gainers & High Yield Stock Recommendations - newser.com
B. Riley Comments on Harrow's Q4 Earnings (NASDAQ:HROW) - MarketBeat
Harrow announces leadership changes, Andrew Boll to serve as President and CFO - MSN
B. Riley Securities Reiterates Harrow (HROW) Buy Recommendation - Nasdaq
HROW: B. Riley Securities Increases Price Target to $74, Reitera - GuruFocus
Harrow to purchase Melt Pharmaceuticals - Eyes On Eyecare
B. Riley Adjusts Price Target on Harrow to $74 From $70, Maintains Buy Rating - MarketScreener
William Blair Issues Positive Outlook for Harrow Earnings - MarketBeat
What is William Blair's Estimate for Harrow FY2025 Earnings? - MarketBeat
Lake Street Maintains Harrow (HROW) Buy Recommendation - Nasdaq
Harrow (NASDAQ:HROW) Shares Gap UpStill a Buy? - MarketBeat
HROW Analyst Update: Lake Street Raises Price Target to $70 | HR - GuruFocus
H.C. Wainwright reiterates Buy rating on Harrow Health stock, maintains $64 target - Investing.com Australia
HC Wainwright Reaffirms Buy Rating for Harrow (NASDAQ:HROW) - MarketBeat
1.54%
1.20%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):